Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer
Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer
复制标题
从全基因组 microRNA 分析中鉴定出的血清 microRNA 表达特征可作为膀胱癌诊断和复发的新型非侵入性生物标志物
DOI：
10.1002/ijc.29041
复制
发表时间：
2015-02-15
影响因子：
6.4
通讯作者：
Wang, Chuanxin
中科院分区：
文献类型：
--
作者：
Jiang, Xiumei;Du, Lutao;Wang, Chuanxin
血清microRNAs(MiRNAs)的新优势为膀胱癌(BC)的无创诊断和预后开辟了新的领域。我们研究的目的是确定BC患者血清miRNA的表达特征，并建立新的BC诊断和复发预测模型。我们通过MiSeq测序对250名BC患者和240名对照的血清样本进行了全基因组的miRNA分析，然后使用逆转录实时定量聚合酶链式反应(RT-FQ)对训练集和验证集进行了评估。用多元Logistic回归模型建立了6个miRNA板(miR-152、miR-148B-3p、miR-3187-3p、miR-15b-5p、miR-27a-3p和miR-30a-5p)，其受试者工作特征曲线下面积为0.899。Ta、T1和T2-T4的敏感性分别为90.00%、84.85%和89.36%，显著高于尿细胞学的13.33%、30.30%和44.68%(P均<0.05)。
Recent advantages of serum microRNAs (miRNAs) open a new realm of possibilities for noninvasive diagnosis and prognosis of bladder cancer (BC). The aim of our study was to identify serum miRNA expression signatures in patients with BC and establish new models for the diagnosis of BC and recurrence prediction. We performed genome-wide serum miRNA analysis by Miseq sequencing followed by evaluations in the training and validation sets with reverse transcription quantitative real-time PCR assays from serum samples of 250 patients with BC and 240 controls. A six-miRNA panel (miR-152, miR-148b-3p, miR-3187-3p, miR-15b-5p, miR-27a-3p and miR-30a-5p) for the diagnosis of BC was finally developed by multivariate logistic regression model with an area under the receiver operating characteristic curve of 0.899. The corresponding sensitivities of this panel for Ta, T1 and T2-T4 were 90.00, 84.85 and 89.36%, significantly higher than those of urine cytology, which were 13.33, 30.30 and 44.68%, respectively (all at p